Skip to content

Erasca, Inc. ERAS Total Liabilities

Total Liabilities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$66.37B-11.5%
Pfizer logo
PfizerPFE
$3.41B-97.1%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$753.82M+162%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$44.29M-58.8%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$93.08M+21.7%
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.69B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s total liabilities?
Erasca, Inc. (ERAS) reported total liabilities of $67.71M in Q1 2026.
How has Erasca, Inc.'s total liabilities changed year-over-year?
Erasca, Inc.'s total liabilities decreased by 5.6% year-over-year, from $71.74M to $67.71M.
What is the long-term trend for Erasca, Inc.'s total liabilities?
Over 5 years (2020 to 2025), Erasca, Inc.'s total liabilities has grown at a 32.5% compound annual growth rate (CAGR), from $17.4M to $70.98M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.